<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04270136</url>
  </required_header>
  <id_info>
    <org_study_id>PI2018_843_0061</org_study_id>
    <nct_id>NCT04270136</nct_id>
  </id_info>
  <brief_title>Feasibility of Total Mastectomy in Ambulatory Care</brief_title>
  <acronym>AMASTEC</acronym>
  <official_title>Feasibility of Total Mastectomy in Ambulatory Care</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Universitaire, Amiens</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Centre hospitalier de Beauvais</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Centre Hospitalier de Saint-Quentin</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Centre Hospitalier Universitaire, Amiens</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Breast cancer is the first female cancer in France. Total mastectomy occurred in 30% of
      breast cancer patient population.

      The purpose of this study is to evaluate the feasibility of outpatient surgery for the total
      mastectomy.

      In France, Ambulatory care is developed as part of the new national health plan.

      Breast conserving surgery for tumorectomy or partial mastectomy is already done in outpatient
      vacation.

      Total mastectomy is an extension of this surgery, and, as such, underpins the investigator's
      hypothesis that total mastectomy is feasible in outpatient care .
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">February 2020</start_date>
  <completion_date type="Anticipated">March 2022</completion_date>
  <primary_completion_date type="Anticipated">February 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>number of ambulatory care after total mastectomy allowed with PADSS score</measure>
    <time_frame>day 0= day of surgery</time_frame>
    <description>Post Anaesthetic Discharge Scoring System (PADSS), which considers six criteria: vital signs, ambulation, nausea/vomiting, pain, bleeding and voiding. Each criterion is given a score ranging from 0 to 2. Only patients who achieve a score of 9 or more are considered ready for discharge.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Breast Cancer</condition>
  <condition>Mastectomy</condition>
  <condition>Ambulatory Care</condition>
  <arm_group>
    <arm_group_label>breast cancer mastectomy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>total mastectomy</intervention_name>
    <description>breast cancer non conserving surgery</description>
    <arm_group_label>breast cancer mastectomy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  All patient with an indication of breast non conserving surgery

        Exclusion Criteria:

          -  Standard contra-indication for ambulatory care.

          -  Also bilateral surgery and immediate breast reconstruction.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <gender_description>female with breast cancer</gender_description>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Elodie Demblocque, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>CH Beauvais</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Albine Mancaux, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>CH Beauvais</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Pierrick Theret, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>CH Saint Quentin</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Arthur Foulon, MD</last_name>
    <phone>(33)3 22 66 88 20</phone>
    <email>foulon.arthur@chu-amiens.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>CHU Amiens</name>
      <address>
        <city>Amiens</city>
        <zip>80480</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Arthur Foulon, MD</last_name>
      <phone>(33)3 22 66 88 20</phone>
      <email>foulon.arthur@chu-amiens.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>February 12, 2020</study_first_submitted>
  <study_first_submitted_qc>February 13, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">February 17, 2020</study_first_posted>
  <last_update_submitted>February 13, 2020</last_update_submitted>
  <last_update_submitted_qc>February 13, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 17, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Breast Cancer</keyword>
  <keyword>mastectomy</keyword>
  <keyword>ambulatory care</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

